INTRODUCTION
Polypeptide growth factors are multifunctional agents affecting a wide variety of cellular functions. Although growth factors represent attractive targets for drug development, only a few antagonists have so far been identified. One promising group of growth-factor antagonists are polysulphates. Suramin is the best characterized of these compounds and has been shown to inhibit the binding of platelet-derived growth factor (PDGF) (Williams et al., 1984) , basic fibroblast growth factor (bFGF) and transforming growth factor , (TGF,/) (Coffey et al., 1987) , and, to a lesser extent, of insulin-like growth factor 1 (IGFI) (Pollak and Richard, 1990) , transforming growth factor ac (TGFx) (Hoffman and Cameron, 1992) and epidermal growth factor (EGF) (Coffey et al., 1987) . Suramin has shown some clinical activity, but this is frequently associated with significant toxicity (Myers et al., 1992) . The polysulphated polysaccharide heparin and related heparin-like molecules modulate the activities of acidic fibroblast growth factor (aFGF) and bFGF (reviewed by Klagsburn, 1990) . The activities of FGFs are also modulated by some synthetic polysulphated polysaccharides including dextran sulphate (Tardieu et al., 1992) and pentosan polysulphate, which inhibited Kaposi's-sarcoma-derived growth factor and was active in animal models (Wellstein et al., 1991) .
The carrageenans are a family of sulphated polysaccharides isolated from red algae. The backbone structure of carrageenans consists of the repeating disaccharide unit (1-÷4)-,/-D-galactopyranosyl-(1-*3)-a-D-galactopyranosyl, with 3,6-anhydrogalactose residues commonly present. Carrageenans differ in their patterns and degree of sulphation, and this has marked effects on their physico-chemical properties (Rees et al., 1982) . Carrageenans are extensively used in the food industry, and while this is not associated with any acute toxicity, carrageenans can exert a number of physiological effects including modulation of immune function (Vijayakumar and Muthukkaruppan, 1990) , anti-viral activity (Girond et al., 1991) and anti-metastatic activity (Coombe et al., 1987) . In this report, the effects of carrageenans on the binding of a range of growth factors has been evaluated. was the most potent TGFfl1 antagonist (IC50 = 19 + 2,tg/ml). None of the carrageenans, at concentrations up to 200 ,ag/ml, inhibited binding of insulin-like growth factor 1 or transforming growth factor cx. Carrageenans are selective growth-factor antagonists and have potential for the treatment of disorders associated with the over-production of certain growth factors.
MATERIALS AND METHODS Carrageenans
All carrageenans were purchased from Sigma Chemical Co., Poole, Dorset, U.K. Carrageenans were made up fresh before each experiment at a concentration of 2 mg/ml in 25 mM Hepes, pH 7.4, heated to 60 'C. The essential features of the carrageenans used in this study are shown in Growth-factor-binding experiments were performed three times with duplicate determinations in each experiment.
RESULTS
The activities of the carrageenans as growth-factor antagonists were investigated by examining their abilities to modulate binding of radiolabelled growth factors to cells. Carrageenans were mixed with ligand just before addition to the cells. Pre-incubation of carrageenans with ligand for periods of up to 2 h did not affect subsequent inhibition of growth-factor binding (results not shown). All of the carrageenans tested inhibited binding of bFGF to BHK cells, with c-carrageenan being the most potent inhibitor. The results of a typical experiment are shown in Figure  1 . The results are expressed in terms of inhibition of total binding rather than specific binding (total minus non-specific), since the carrageenans were able to reduce binding to below non-specific binding values. (Non-specific binding represented approx. 45 % of total binding as determined using 50 nM bFGF, a 500-fold excess over labelled bFGF.) BHK cells express both low-and high-affinity receptors (Moscatelli, 1987) is shown in Figure 2 . Interestingly, the order of potency was different from that for inhibition of bFGF binding. For inhibition of PDGF binding, K-carrageenan and A-carrageenan were more potent antagonists than t-carrageenan.
The effects of carrageenans on specific binding of TGF,81 were examined using Swiss 3T3 cells. The activity of the carrageenans as TGF/31 antagonists was significantly weaker than the activity of these compounds as inhibitors of bFGF or PDGF binding (Figure 3) . The effects of carrageenans on specific binding of IGF1 were examined using L23/P cells. Non-specific binding was IO°. of total binding. A-Carrageenan, at concentrations up to 250 ,ug/ml, did not significantly inhibit specific binding of IGFI to L23/P cells (Figure 4 ). i-Carrageenan and K-carrageenan at 200 ,tg/ml did not inhibit binding of IGFI (results not shown). Suramin, a known antagonist of IGF 1 binding (Pollack and Richard, 1990) , was used as a positive control in this experiment and caused 10000 inhibition of IGF1 binding at a final concentration of 200 ,tg/ml (results not shown). t-Carrageenan at concentrations up to 200 ,ug/ml had no effect on TGFax binding to A431 cells (Figure 4) . (Non-specific binding was 12 0,/o.) Neither A-carrageenan nor K-carrageenan at 200 ,ug/ml inhibited TGFa binding (results not shown). Suramin was used as a positive control in this experiment (Hoffman and Cameron, 1992) (Coffey et al., 1987) . Thus the carrageenans show more discrimination as inhibitors of growth-factor binding than does suramin. The precise mechanism by which polysulphates inhibit the interaction between growth factors and their receptors has not been determined. The ability of suramin to inhibit the interaction between PDGF and its receptor appears to be due to binding of suramin to PDGF rather than the PDGF receptor (Hosang, 1985) . FGFs characteristically bind to heparin, and the structural similarity of polysulphated carbohydrates with heparin suggests that polysulphated carbohydrates may interact with the heparinbinding domain on FGFs. BHK cells express both heparin-like low-affinity receptors and high-affinity receptors (Moscatelli, 1987) . Both PDGF and TGF,f1 bind to heparin (Vlodavsky et al., 1987; McCaffrey et al., 1992) , and this may explain the abilities of the carrageenans to inhibit binding of these growth factors. To the best of the author's knowledge, there are no reports of either TGFa or IGFI binding to heparin, and neither of these growth factors were inhibited by the carrageenans.
Of particular interest in the present study is the observation that the carrageenans showed some selectivity in their inhibition of growth-factor binding and that no one carrageenan was, overall, the most potent growth-factor antagonist. The interaction between polysulphated carbohydrates and proteins has been shown, in some instances, to display a remarkable degree of selectivity, the best-defined example being the interaction between heparin and anti-thrombin III (Van Boeckel et al., 1991) . The structural differences between carrageenans in terms of their degrees of sulphation and carbohydrate backbone indicates that this may confer on them an ability to interact selectively with domains on growth factors.
The aberrant production of growth factors is associated with a large number of pathological conditions. For example, bFGF production is implicated in the proliferation and neo-vascularization of tumours (Baird and Bohlen, 1991 
